Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palazestrant SCHEMBL20528170 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL24885107 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL30128723 | 1.00 | ESR1 (0.78) | ESR1PGR | |
| SCHEMBL26424146 | 0.92 | ESR1 (0.67) | ESR1PGR | |
| SCHEMBL30123563 | 0.92 | ESR1 (0.79) | ESR1PGR | |
| SCHEMBL17839179 | 0.92 | ESR1 (0.79) | ESR1PGR | |
| SCHEMBL23280600 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL20528169 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL29358188 | 0.88 | ESR1 (0.75) | ESR1 | |
| SCHEMBL25002345 | 0.88 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076626-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024015506-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023225354-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023221122-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225353-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023221123-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023091550-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3912680-A1 | TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3355884-B1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |